Stryker Corporation reported a robust fourth‑quarter 2025 performance, with revenue of $7.17 billion—up 11.4% year‑over‑year—and a full‑year revenue of $25.1 billion. Organic sales grew 11.0% in the quarter and 10.3% for the year, driven by strong demand in MedSurg and Neurotechnology, which each posted 12.6% organic growth, while Orthopaedics and Spine added 8.4%. The company’s capital‑equipment business, led by the Mako robotic platform, continued to expand, with record installations and a growing install base that now exceeds 3,000 systems worldwide.
The company’s earnings beat expectations: quarterly adjusted earnings per share were $4.47, surpassing the consensus estimate of $4.40 by $0.07, a 1.7% beat. Full‑year adjusted EPS rose to $13.63, up 11.8% from the prior year. Operating margin expanded by 100 basis points to 30.2% in the quarter and 26.3% for the year, reflecting lower adjusted SG&A as a percentage of sales and a favorable product mix.
Margin expansion was driven by several factors. The company’s high‑margin MedSurg and Neurotechnology segments grew faster than the rest of the business, offsetting modest gross‑margin compression from tariff impacts. Pricing power on the Mako system helped lift revenue per unit, while cost efficiencies from the Inari acquisition integration—though not fully quantified in the earnings release—contributed to lower operating expenses. The company also benefited from a shift toward higher‑margin capital‑equipment sales, which helped cushion the impact of competitive pressures in its vascular ischemic business.
Stryker raised its full‑year 2026 adjusted EPS guidance to $14.90–$15.10, a modest upward revision that signals confidence in continued demand for its high‑margin products. Management highlighted robust capital‑equipment demand, the continued success of the Mako platform, and the launch of new high‑margin offerings such as the Triathlon Gold and RPS systems. Headwinds remain, including a projected $400 million tariff impact in 2026—an increase of $200 million over 2025—and competitive pressure in the vascular segment, but the company expects these to be offset by strong procedural volumes and pricing power.
The market reaction was muted, with investors focusing on the guidance rather than the slight revenue miss. Analysts noted the earnings beat and margin expansion as evidence of effective cost control and a favorable product mix, while the modest revenue shortfall was attributed to tariff headwinds and a slower capital‑spending environment in Europe. Overall, the results reinforce Stryker’s trajectory of double‑digit revenue growth and margin expansion, positioning the company well for the 2026 operating environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.